Zyversa Therapeutics Stock Analysis
| ZVSA Stock | 2.16 0.04 1.82% |
ZyVersa Therapeutics is undervalued with Real Value of 2.29 and Hype Value of 2.25. The main objective of ZyVersa Therapeutics stock analysis is to determine its intrinsic value, which is an estimate of what ZyVersa Therapeutics is worth, separate from its market price. There are two main types of ZyVersa Therapeutics' stock analysis: fundamental analysis and technical analysis.
The ZyVersa Therapeutics stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. Here, you can get updates on important government artifacts, including earning estimates, SEC corporate filings, announcements, and ZyVersa Therapeutics' ongoing operational relationships across important fundamental and technical indicators.
ZyVersa |
ZyVersa Stock Analysis Notes
The company has Price to Book (P/B) ratio of 0.27. Historically many companies with similar price-to-book (P/B) ratio do better than the market in the long run. ZyVersa Therapeutics recorded earning per share (EPS) of 1163.36. The entity had not issued any dividends in recent years. The firm had 1:10 split on the 26th of April 2024. For more information please call the company at 754 231 1688 or visit https://www.zyversa.com.ZyVersa Therapeutics Investment Alerts
Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. ZyVersa Therapeutics' investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding ZyVersa Therapeutics or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
| ZyVersa Therapeutics generated a negative expected return over the last 90 days | |
| ZyVersa Therapeutics has high historical volatility and very poor performance | |
| ZyVersa Therapeutics has high likelihood to experience some financial distress in the next 2 years | |
| Net Loss for the year was (98.3 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| ZyVersa Therapeutics generates negative cash flow from operations | |
| ZyVersa Therapeutics has a frail financial position based on the latest SEC disclosures |
ZyVersa Therapeutics Upcoming and Recent Events
Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to ZyVersa Therapeutics previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 13th of February 2024 Upcoming Quarterly Report | View | |
| 10th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 13th of February 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
ZyVersa Market Capitalization
The company currently falls under 'Nano-Cap' category with a current market capitalization of 2.36 M.Technical Drivers
As of the 23rd of September, ZyVersa Therapeutics maintains the Market Risk Adjusted Performance of 0.2205, mean deviation of 5.44, and Standard Deviation of 8.32. Relative to fundamental indicators, the technical analysis model lets you check existing technical drivers of ZyVersa Therapeutics, as well as the relationship between them.ZyVersa Therapeutics Price Movement Analysis
The output start index for this execution was two with a total number of output elements of fifty-nine. The Bollinger Bands is very popular indicator that was developed by John Bollinger. It consist of three lines. ZyVersa Therapeutics middle band is a simple moving average of its typical price. The upper and lower bands are (N) standard deviations above and below the middle band. The bands widen and narrow when the volatility of the price is higher or lower, respectively. The upper and lower bands can also be interpreted as price targets for ZyVersa Therapeutics. When the price bounces off of the lower band and crosses the middle band, then the upper band becomes the price target.
ZyVersa Therapeutics Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific ZyVersa Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on ZyVersa Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases ZyVersa Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Stephen Glover over two months ago Acquisition by Stephen Glover of 3022 shares of ZyVersa Therapeutics subject to Rule 16b-3 | ||
Labella Nicholas A. Jr. over three months ago Acquisition by Labella Nicholas A. Jr. of 59563 shares of ZyVersa Therapeutics subject to Rule 16b-3 |
ZyVersa Therapeutics Predictive Daily Indicators
ZyVersa Therapeutics intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of ZyVersa Therapeutics stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
ZyVersa Therapeutics Forecast Models
ZyVersa Therapeutics' time-series forecasting models are one of many ZyVersa Therapeutics' stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary ZyVersa Therapeutics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.Be your own money manager
As an investor, your ultimate goal is to build wealth. Optimizing your investment portfolio is an essential element in this goal. Using our stock analysis tools, you can find out how much better you can do when adding ZyVersa Therapeutics to your portfolios without increasing risk or reducing expected return.Did you try this?
Run Stock Screener Now
Stock ScreenerFind equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. |
| All Next | Launch Module |
Complementary Tools for ZyVersa Stock analysis
When running ZyVersa Therapeutics' price analysis, check to measure ZyVersa Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ZyVersa Therapeutics is operating at the current time. Most of ZyVersa Therapeutics' value examination focuses on studying past and present price action to predict the probability of ZyVersa Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ZyVersa Therapeutics' price. Additionally, you may evaluate how the addition of ZyVersa Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities |